Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.71 |
| ▸ | CDK4 | P11802 | 1/20 | 0.71 |
| ▸ | CCND1 | P24385 | 1/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427029 | 1.00 | GSK3B (1.00) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL29396453 | 1.00 | GSK3B (1.00) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL8154180 | 0.86 | GSK3B (0.76) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL24393899 | 0.86 | GSK3B (0.76) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL4421134 | 0.86 | GSK3B (0.76) | GSK3BPRKCACDK2 | |
| SCHEMBL4418475 | 0.86 | GSK3B (0.76) | GSK3BPRKCACDK4CCND1CDK2 | |
| SCHEMBL7054131 | 0.86 | CCNE2 (0.76) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL8162809 | 0.86 | CCNE2 (0.76) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL8166880 | 0.86 | GSK3B (0.81) | GSK3BPRKCACCNE2CDK4CCND1 | |
| SCHEMBL6950992 | 0.86 | GSK3B (0.94) | GSK3BPRKCACCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA (IT) | 2026-04-30 | — | — | US | claimed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | claimed |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4594471-A1 | METHODS FOR THE PRODUCTION OF CARDIAC FIBROBLASTS | Fujifilm Cellular Dynamics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4594475-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | Università degli Studi di Modena e Reggio Emilia (IT) | 2025-08-06 | — | — | EP | claimed |
| US-20250092358-A1 | In Vitro Breeding Systems and Methods in Livestock | ABS GLOBAL, INC. (US) | 2025-03-20 | — | — | US | claimed |
| US-20250075175-A1 | EFFICIENT DERIVATION OF STABLE PLURIPOTENT BOVINE EMBRYONIC STEM CELLS | UNIV CALIFORNIA (US) | 2025-03-06 | — | — | US | claimed |
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| CN-119490952-A | In vitro induction of blastocysts and uses thereof | 广州国家实验室 | 2025-02-21 | — | — | CN | claimed |
| WO-2022251549-A1 | IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK | ABS GLOBAL, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| CN-113430229-B | Construction method of human-derived BAV-TAA disease pluripotent stem cell model | 温州医科大学 | 2022-11-22 | — | — | CN | claimed |
| US-20220323753-A1 | Methods of Treating Neurodegenerative Disorders with Alternating Electric Fields | NOVOCURE GMBH (CH) | 2022-10-13 | — | — | US | claimed |
| WO-2022215051-A1 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-10-13 | — | — | WO | claimed |
| CN-114874973-A | Culture medium and culture method for obtaining mature hepatocytes | 深圳市三启生物技术有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114540278-A | Microvessel in-vitro culture method and culture solution | 青岛大学 | 2022-05-27 | — | — | CN | claimed |
| WO-2022051847-A9 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-114369577-A | Cattle induced expansion pluripotent adult stem cell, line establishing method and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| CN-114369567-A | Method for establishing bovine expanded pluripotent embryonic stem cells and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| WO-2022051847-A1 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | HDAC5, HDAC6, GSK3B | GSK3B 3/4885PRKCA 1679/4885CCNE2 4530/4885 |
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | GSK3B, GSK3A, EPCAM | GSK3B 1/4885PRKCA 227/4885CCNE2 2105/4885 |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | WNT1, PHKA1, ACVR1 | GSK3B 315/4885PRKCA 3225/4885CCNE2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.